1. Home
  2. SCHW vs AMGN Comparison

SCHW vs AMGN Comparison

Compare SCHW & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Charles Schwab Corporation (The)

SCHW

Charles Schwab Corporation (The)

N/A

Current Price

$90.70

Market Cap

180.9B

Sector

Finance

ML Signal

N/A

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$437.81

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SCHW
AMGN
Founded
1971
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
180.9B
251.6B
IPO Year
2007
2002

Fundamental Metrics

Financial Performance
Metric
SCHW
AMGN
Price
$90.70
$437.81
Analyst Decision
Buy
Hold
Analyst Count
24
34
Target Price
$116.64
★ $435.77
AVG Volume (30 Days)
★ 7.8M
2.1M
Earning Date
10-15-2026
11-03-2026
Dividend Yield
1.39%
★ 2.30%
EPS Growth
55.52
★ 88.23
EPS
4.53
★ 14.79
Revenue
$23,921,000,000.00
★ $25,424,000,000.00
Revenue This Year
$17.48
$7.45
Revenue Next Year
$12.57
$4.54
P/E Ratio
★ $20.34
$29.67
Revenue Growth
★ 22.01
8.83
52 Week Low
$83.96
$312.39
52 Week High
$114.53
$483.99

Technical Indicators

Market Signals
Indicator
SCHW
AMGN
Relative Strength Index (RSI) 41.70 41.75
Support Level $88.67 $338.02
Resistance Level $94.11 $446.42
Average True Range (ATR) 2.19 11.75
MACD 0.34 -4.96
Stochastic Oscillator 33.71 4.16

Price Performance

Historical Comparison
SCHW
AMGN

About SCHW Charles Schwab Corporation (The)

Charles Schwab is one of the largest retail-oriented financial-services companies in the US, with $11.9 trillion in client assets across its brokerage, banking, asset management, custody, financial advisory, and wealth management businesses at the end of 2025. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset management segments. The firm is a dominant player in Registered Investment Advisor (RIA) custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: